MCRB
Income statement / Annual
Last year (2024), Seres Therapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Seres Therapeutics, Inc.'s net income was $136,000.00.
See Seres Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$126.33 M |
$7.13 M |
$144.93 M |
$33.22 M |
$34.51 M |
$28.27 M |
$32.10 M |
$21.77 M |
$0.00 |
| Cost of Revenue |
$0.00
|
$704,000.00
|
$1.00 M
|
$1.73 M
|
$90.57 M
|
$80.14 M
|
$95.96 M
|
$89.46 M
|
$81.99 M
|
$728,000.00
|
| Gross Profit |
$0.00
|
$125.62 M
|
$6.12 M
|
$143.20 M
|
-$57.36 M
|
-$45.64 M
|
-$67.69 M
|
-$57.36 M
|
-$60.22 M
|
-$728,000.00
|
| Gross Profit Ratio |
0
|
0.99
|
0.86
|
0.99
|
-1.73
|
-1.32
|
-2.39
|
-1.79
|
-2.77
|
0
|
| Research and Development Expenses |
$64.60 M
|
$145.86 M
|
$172.92 M
|
$141.89 M
|
$90.57 M
|
$80.14 M
|
$95.96 M
|
$89.46 M
|
$81.99 M
|
$38.10 M
|
| General & Administrative Expenses |
$53.18 M
|
$87.74 M
|
$79.69 M
|
$69.26 M
|
$30.78 M
|
$24.75 M
|
$32.60 M
|
$34.04 M
|
$32.62 M
|
$16.76 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$53.18 M
|
$87.74 M
|
$79.69 M
|
$69.26 M
|
$30.78 M
|
$24.75 M
|
$32.60 M
|
$34.04 M
|
$32.62 M
|
$16.76 M
|
| Other Expenses |
$3.53 M
|
$0.00
|
$1.00 M
|
-$1.73 M
|
$981,000.00
|
$1.07 M
|
$170,000.00
|
$425,000.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$121.32 M
|
$233.60 M
|
$253.62 M
|
$209.42 M
|
$121.35 M
|
$104.89 M
|
$128.55 M
|
$123.50 M
|
$114.61 M
|
$54.86 M
|
| Cost And Expenses |
$0.00
|
$234.31 M
|
$253.62 M
|
$209.42 M
|
$121.35 M
|
$104.89 M
|
$128.55 M
|
$123.50 M
|
$114.61 M
|
$54.86 M
|
| Interest Income |
$3.97 M
|
$7.30 M
|
$3.06 M
|
$2.87 M
|
$946,000.00
|
$1.03 M
|
$0.00
|
$0.00
|
$2.23 M
|
$638,000.00
|
| Interest Expense |
$0.00
|
$13.18 M
|
$6.02 M
|
$2.91 M
|
$2.92 M
|
$502,000.00
|
$1.17 M
|
$1.59 M
|
$969,000.00
|
$555,000.00
|
| Depreciation & Amortization |
$4.46 M
|
$6.24 M
|
$11.85 M
|
$9.22 M
|
$8.89 M
|
$9.83 M
|
$7.86 M
|
$7.26 M
|
$4.21 M
|
$728,000.00
|
| EBITDA |
-$121.32 M |
-$94.31 M |
-$237.51 M |
-$56.72 M |
-$77.31 M |
-$59.95 M |
-$91.08 M |
-$82.12 M |
-$88.63 M |
-$54.13 M |
| EBITDA Ratio |
0
|
-0.75
|
-33.32
|
-0.39
|
-2.33
|
-1.74
|
-3.22
|
-2.56
|
-4.07
|
0
|
| Operating Income Ratio |
0
|
-0.85
|
-34.58
|
-0.45
|
-2.65
|
-2.08
|
-3.55
|
-2.85
|
-4.27
|
0
|
| Total Other Income/Expenses Net |
$121.45 M
|
-$5.74 M
|
-$3.67 M
|
-$1.09 M
|
-$997,000.00
|
$1.60 M
|
$1.34 M
|
$2.02 M
|
$1.26 M
|
$76,000.00
|
| Income Before Tax |
$136,000.00
|
-$113.72 M
|
-$250.16 M
|
-$65.58 M
|
-$89.13 M
|
-$70.28 M
|
-$98.94 M
|
-$89.38 M
|
-$91.58 M
|
-$54.78 M
|
| Income Before Tax Ratio |
0
|
-0.9
|
-35.09
|
-0.45
|
-2.68
|
-2.04
|
-3.5
|
-2.78
|
-4.21
|
0
|
| Income Tax Expense |
$136,000.00
|
$0.00
|
$3.67 M
|
-$4.08 M
|
-$2.67 M
|
-$6.04 M
|
$1.34 M
|
-$1.59 M
|
$2.23 M
|
-$804,000.00
|
| Net Income |
$136,000.00
|
-$113.72 M
|
-$253.82 M
|
-$61.50 M
|
-$86.45 M
|
-$64.24 M
|
-$98.94 M
|
-$89.38 M
|
-$91.58 M
|
-$54.78 M
|
| Net Income Ratio |
0
|
-0.9
|
-35.61
|
-0.42
|
-2.6
|
-1.86
|
-3.5
|
-2.78
|
-4.21
|
0
|
| EPS |
0.0009 |
-0.89 |
-2.35 |
-0.67 |
-1.08 |
-1.13 |
-2.43 |
-2.21 |
-2.3 |
-2.33 |
| EPS Diluted |
0.0009 |
-0.89 |
-2.35 |
-0.67 |
-1.08 |
-1.13 |
-2.43 |
-2.21 |
-2.3 |
-2.33 |
| Weighted Average Shares Out |
$155.40 M
|
$128.00 M
|
$108.08 M
|
$91.70 M
|
$79.79 M
|
$56.65 M
|
$40.74 M
|
$40.45 M
|
$39.85 M
|
$23.53 M
|
| Weighted Average Shares Out Diluted |
$155.40 M
|
$128.00 M
|
$108.08 M
|
$91.70 M
|
$79.79 M
|
$56.65 M
|
$40.74 M
|
$40.45 M
|
$39.85 M
|
$23.53 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
